People · Operator
Named in public records as an officer, director or promoter · active 2018–2018 · Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| WindMIL Therapeutics, Inc. | — | Biotechnology | Series B | $44.9M | $72.5M | 2018 |
Howard Soule at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Howard Soule on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Brian Halak | 1 | 10 |
| Brian Dovey | 1 | 7 |
| Donald J. Hayden, Jr. | 1 | 5 |
| Donald Hayden, Jr. | 1 | 3 |
| Allan Fox | 1 | 2 |
| Daniel J. O'Donnell | 1 | 1 |
| Mark J. McDade | 1 | 1 |
| Howard J. Soule | 1 | 1 |
| Brian J. Dovey | 1 | 1 |
| Patrick J. Fabbio | 1 | 1 |
| Anna J. French | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.